Eli Lilly Gains 4.6% as Goldman Sachs Lifts Price Target to $1,413
Eli Lilly shares rose 4.6% to a record high after Goldman Sachs raised its price target to $1,413 and maintained a Buy rating. BofA also increased its target to $1,397. Analysts expect revenue of $88.5 billion this year, with Q3 results due on October 29.
How this was made
The 30-second read
Why it matters
The analyst upgrades provide a fresh catalyst, likely prompting short-term buying.
Market read
Analyst upgrades drive a notable intraday move, offering a short-term trading opportunity.
What to watch
Upcoming Q3 earnings could reveal whether the price target is justified.
Background
Goldman Sachs and BofA both raised price targets for Eli Lilly after recent earnings and market trends.
Ticker impact
Goldman Sachs raised its price target to $1,413, prompting a 4.6% intraday rise in Eli Lilly shares.
likely upward pressure as investors price in the higher target
Analyst upgrade with a concrete price target increase is a fresh catalyst driving the stock higher.
Market effects
The upgrade may lift other large pharma stocks as the sector benefits from analyst optimism.
U.S. market sentiment for healthcare equities could improve.
Limited to U.S. and global pharma investors tracking Lilly.
Counterpoint
The target may be overly optimistic given potential demand slowdown for obesity drugs.
Key entities
- companyEli Lilly
Pharmaceutical company (ticker LLY) subject of price target upgrades.
- financial_institutionGoldman Sachs
Analyst raising price target for LLY.
